Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study

Heike U Krämer, Elke Raum, Gernot Rüter, Ben Schöttker, Dietrich Rothenbacher, Thomas Rosemann, Joachim Szecsenyi, Hermann Brenner, Heike U Krämer, Elke Raum, Gernot Rüter, Ben Schöttker, Dietrich Rothenbacher, Thomas Rosemann, Joachim Szecsenyi, Hermann Brenner

Abstract

Background: Coronary heart disease (CHD) is one of the most common long-term complications in people with type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among people with type 2 diabetes.

Methods: The study was based on data from the baseline examination of the DIANA study, a prospective cohort study of 1,146 patients with type 2 diabetes conducted in South-West Germany. Information on diabetes and CHD medication was obtained from the physician questionnaires. Bivariate and multivariate analyses using logistic regression were employed in order to assess associations between gender and prescribed drug classes.

Results: In total, 624 men and 522 women with type 2 diabetes with a mean age of 67.2 and 69.7 years, respectively, were included in this analysis. Compared to women, men had more angiopathic risk factors, including smoking, alcohol consumption and worse glycemic control, and had more often a diagnosed CHD. Bivariate analyses showed higher prescription of thiazolidinediones and oral combination drugs as well as of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers and aspirin in men than in women. After full adjustment, differences between men and women remained significant only for ACE inhibitors (OR=1.44; 95%-confidence interval (CI): 1.11-1.88) and calcium channel blockers (OR=1.42, 95%-CI: 1.05-1.91).

Conclusions: These findings contribute to current discussions on gender differences in diabetes care. Men with diabetes are significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers in the presence of coronary heart disease, respectively. Our results suggest, that diabetic men might be more thoroughly treated compared to women. Further research is needed to focus on reasons for these differences mainly in treatment of cardiovascular diseases to improve quality of care.

Trial registration: ClinicalTrials.gov NCT00742547.

Figures

Figure 1
Figure 1
Mean number (± standard error) of diabetes medication by glycemic control.
Figure 2
Figure 2
Mean number (± standard error) of diabetes medication by diabetes duration.

References

    1. Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with diabetes. Nutr Metab Cardiovasc Dis. 2010;20:474–480. doi: 10.1016/j.numecd.2010.01.008.
    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–1757. doi: 10.1016/S0140-6736(06)68770-9.
    1. Hayashi T, Kawashima S, Nomura H, Itoh H, Watanabe H, Ohrui T, Yokote K, Sone H, Hattori Y, Yoshizumi M, Ina K, Kubota K. the Japan Cholesterol and Diabetes Mellitus Investigation Group. Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and stroke among elderly diabetic patients. Cardiovasc Diabetol. 2011;10:86. doi: 10.1186/1475-2840-10-86.
    1. Mercuro G, Deidda M, Piras A, Dessalvi CC, Maffei S, Rosano GM. Gender determinants of cardiovascular risk factors and diseases. J Cardiovasc Med. 2010;11:207–220.
    1. Heisler M, Piette JD, Spencer M, Kieffer E, Vijan S. The relationship between knowledge of recent HbA(1c) values and diabetes care understanding and self-management. Diabetes Care. 2005;28:816–822. doi: 10.2337/diacare.28.4.816.
    1. King DK, Glasgow RE, Toobert DJ, Strycker LA, Estabrooks PA, Osuna D, Faber AJ. Self-efficacy, problem solving, and social-environmental support are associated with diabetes self-management behaviors. Diabetes Care. 2010;33:751–753. doi: 10.2337/dc09-1746.
    1. American Diabetes Association (ADA) Standards of medical care in diabetes - 2010. Diabetes Care. 2010;33(Suppl 1):11–61.
    1. Tschöpe C, Schultheiss HP. Diabetic cardiopathy: pathogenesis, diagnosis and therapy. Internist. 2003;44:806–818. doi: 10.1007/s00108-003-0947-z. [Article in German]
    1. Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M, Selby JV. Translating Research Into Action for Diabetes Study Group. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care. 2008;31:69–74. doi: 10.2337/dc08-1082.
    1. Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008;31:1389–1391. doi: 10.2337/dc08-0194.
    1. Roe CM, McNamara AM, Motheral BR. Gender- and age-related prescription drug use patterns. Ann Pharmacother. 2002;36:30–39.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi: 10.1097/00005650-198601000-00007.
    1. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233. doi: 10.1097/00005650-199603000-00003.
    1. American Diabetes Association (ADA) Executive summary: standards of medical care in diabetes - 2010. Diabetes Care. 2010;33(Suppl 1):4–10.
    1. Lehnert H, Wittchen HU, Pittrow D, Bramlage P, Kirch W, Böhler S, Höfler M, Ritz E. Prevalence and pharmacotherapy of diabetes mellitus in primary care. Dtsch Med Wochenschr. 2005;130:323–328. doi: 10.1055/s-2005-863050. [Arctile in German]
    1. Schernthaner G, Forst T, Gulba D, Haberbosch W, Hanefeld M, Linss G, März W, Mehnert H, Rosak C, Schnell O, Seufert J, Tschöpe D, Erdmann E. Challenge in diabetes therapy: effects of glitazones beyond blood glucose control. Dtsch Med Wochenschr. 2009;134:949–954. doi: 10.1055/s-0029-1220255. [Article in German]
    1. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–39. doi: 10.1503/cmaj.080486.
    1. Gemeinsamer Bundesausschuss (GBA) Arzneimittel-Richtlinie/ Anlage III (Glitazone zur Behandlung des Diabetes mellitus Type 2) . 02 July 2012.
    1. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglin. . 02 July 2012.
    1. Lenzen MJ, Rosengren A, op Reimer WJ S, Follath F, Boersma E, Simoons ML, Cleland JG, Komajda M. Management of patients with heart failure in clinical practice: differences between men and women. Heart. 2008;94:e10. doi: 10.1136/hrt.2006.099523.
    1. Baumhäkel M, Müller U, Böhm M. Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail. 2009;11:299–303. doi: 10.1093/eurjhf/hfn041.
    1. Nilsson PM, Theobald H, Journath G, Fritz T. Gender differences in risk factor control and treatment profile in diabetes: a study in 229 swedish primary health care centres. Scand J Prim Health Care. 2004;22:27–31. doi: 10.1080/02813430310003264.
    1. Hasslacher C, Wolf G, Kempe P, Ritz E. Diabetic Nephropathie. Diabetologie und Stoffwechsel. 2010;5(Suppl 2):S113–S116. [Article in German]
    1. Brannström J, Hamberg K, Molander L, Lövheim H, Gustafson Y. Gender disparities in the pharmocological treatment of cardiovascular disease and diabetes mellitus in the very old. Drugs Aging. 2011;28:993–1005. doi: 10.2165/11594730-000000000-00000.
    1. Dallongville J, De Bacquer D, Heidrich J, De Backer G, Prugger C, Kotseva K, Montaye M, Amouyel P. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart. 2010;96:1744–1749. doi: 10.1136/hrt.2010.196170.
    1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591. doi: 10.1056/NEJMoa0706245.
    1. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125. doi: 10.1016/S0140-6736(08)60104-X.
    1. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58:1634–1640. doi: 10.2337/db08-1771.
    1. Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2011. p. CD005158.
    1. Graversen L, Christensen B, Borch-Johnsen K, Lauritzen T, Sandbaek A. General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark. Scand J Prim Health Care. 2010;28:47–54. doi: 10.3109/02813430903335216.
    1. Fu AZ, Zhang Q, Davies MJ, Pentakota SR, Radican L, Seck T. Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study. Curr Med Res Opin. 2011;27:1035–1040. doi: 10.1185/03007995.2011.567257.
    1. Leosdottir M, Willenheimer R, Persson M, Nilsson PM. The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: a cross-sectional analysis within the Malmö preventive project. Cardiovasc Diabetol. 2011;10:118. doi: 10.1186/1475-2840-10-118.
    1. Moebus S, Balijepalli C, Lösch C, Göres L, von Stritzky B, Bramlage P, Wasem J, Jöckel KH. Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factors combinations of the metabolic syndrome –a cross-sectiona study. Cardiovasc Diabetol. 2010;9:34. doi: 10.1186/1475-2840-9-34.
    1. Franconi F, Campesi I, Occhioni S, Tonolo G. Sex-gender differences in diabetes vascular complications and treatment. Endocr Metab Immune Disord Drug Targets. 2012;12:179–196. doi: 10.2174/187153012800493512.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit